{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:11:53Z","timestamp":1779898313689,"version":"3.53.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["ID809"],"award-info":[{"award-number":["ID809"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12883-018-1162-9","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T02:46:31Z","timestamp":1538534791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-4790","authenticated-orcid":false,"given":"G. J.","family":"Melendez-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Armoiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoby","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"issue":"4","key":"1162_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D, Rashid W, Schmierer K, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273\u20139.","journal-title":"Pract Neurol"},{"issue":"52","key":"1162_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21520","volume":"21","author":"GJ Melendez-Torres","year":"2017","unstructured":"Melendez-Torres GJ, Auguste P, Armoiry X, Maheswaran H, Court R, Madan J, Kan A, Lin S, Counsell C, Patterson J, et al. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technol Assess. 2017;21(52):1\u2013352.","journal-title":"Health Technol Assess"},{"key":"1162_CR3","first-page":"CD011381","volume":"9","author":"I Tramacere","year":"2015","unstructured":"Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9:CD011381.","journal-title":"Cochrane Database Syst Rev"},{"key":"1162_CR4","first-page":"CD008933","volume":"6","author":"G Filippini","year":"2013","unstructured":"Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;6:CD008933.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1162_CR5","doi-asserted-by":"publisher","first-page":"e0127960","DOI":"10.1371\/journal.pone.0127960","volume":"10","author":"K Tolley","year":"2015","unstructured":"Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E. A network meta-analysis of efficacy and evaluation of safety of subcutaneous Pegylated interferon Beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One. 2015;10(6):e0127960.","journal-title":"PLoS One"},{"issue":"6","key":"1162_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/jcpt.12090","volume":"38","author":"GM Hadjigeorgiou","year":"2013","unstructured":"Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. J Clin Pharm Ther. 2013;38(6):433\u20139.","journal-title":"J Clin Pharm Ther"},{"key":"1162_CR7","first-page":"Cd005278","volume":"2","author":"M Clerico","year":"2008","unstructured":"Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev. 2008;2:Cd005278.","journal-title":"Cochrane Database Syst Rev"},{"key":"1162_CR8","first-page":"343","volume":"d5928","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;d5928:343.","journal-title":"BMJ (Clinical research ed)"},{"key":"1162_CR9","unstructured":"Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care [\n                    http:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf\n                    \n                  ]."},{"issue":"2","key":"1162_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98\u2013110.","journal-title":"Res Synth Methods"},{"issue":"12","key":"1162_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archneur.1997.00550240029009","volume":"54","author":"CE Schwartz","year":"1997","unstructured":"Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol. 1997;54(12):1475\u201380.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"1162_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jns.2014.01.038","volume":"342","author":"N Mokhber","year":"2014","unstructured":"Mokhber N, Azarpazhooh A, Orouji E, Rao SM, Khorram B, Sahraian MA, Foroghipoor M, Gharavi MM, Kakhi S, Nikkhah K, et al. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci. 2014;342(1\u20132):16\u201320.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1162_CR13","first-page":"3","volume":"5","author":"P Rieckmann","year":"2012","unstructured":"Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R. Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther. 2012;5(1):3\u201312.","journal-title":"Ther"},{"issue":"4","key":"1162_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, Group BS. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261(4):773\u201383.","journal-title":"J Neurol"},{"issue":"12","key":"1162_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. [erratum appears in N Engl J med. 2012 Oct 25;367(17):1673]. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"9805","key":"1162_CR16","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, O\u2019Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779\u201387.","journal-title":"Lancet"},{"key":"1162_CR17","unstructured":"Bayer HealthCare AG. Clinical Study Synopsis: The AVANTAGE study - A randomized, multicenter, phase IV, open-label prospective study comparing injection site reaction and injection site pain in patients with relapsing remitting multiple sclerosis (RRMS) or after a first demyelinating event suggestive of MS newly started on interferon beta-1b (Betaferon\u00ae) or interferon beta-1a (Rebif\u00ae). 2013. \n                    http:\/\/trialfinder.pharma.bayer.com\/omr\/online\/91489_Study_Synopsis_CTP.pdf\n                    \n                  .  Accessed 10 May 2013."},{"issue":"7","key":"1162_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJM198708133170703","volume":"317","author":"MB Bornstein","year":"1987","unstructured":"Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V, et al. A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317(7):408\u201314.","journal-title":"N Engl J Med"},{"key":"1162_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1471-2377-12-154","volume":"12","author":"B Singer","year":"2012","unstructured":"Singer B, Bandari D, Cascione M, LaGanke C, Huddlestone J, Bennett R, Dangond F, Group RS. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonbeta-1a versus subcutaneous interferonbeta-1b: results of the randomized, multicenter, phase IIIb REFORMS study. BMC Neurol. 2012;12:154.","journal-title":"BMC Neurol"},{"issue":"9316","key":"1162_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","volume":"359","author":"L Durelli","year":"2002","unstructured":"Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453\u201360.","journal-title":"Lancet"},{"issue":"Pt 11","key":"1162_CR21","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138(Pt 11):3287\u201398.","journal-title":"Brain"},{"issue":"7","key":"1162_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jclinepi.2014.12.016","volume":"68","author":"ME Flacco","year":"2015","unstructured":"Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A, Scaioli G, De Vito C, Siliquini R, Villari P, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol. 2015;68(7):811\u201320.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"1162_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1352458514559865","volume":"21","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(9):1159\u201371.","journal-title":"Mult Scler"},{"issue":"12","key":"1162_CR24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","volume":"72","author":"J Cohen","year":"2015","unstructured":"Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberye J, van den Tweel E, Mulder R, Koper N, Voortman G, et al. Equivalence of generic Glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015;72(12):1433\u201341.","journal-title":"JAMA Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-018-1162-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-018-1162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T19:19:18Z","timestamp":1570043958000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-018-1162-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1186\/s12883-018-1162-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not require ethics approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Olga Ciccarelli received consultancy fees from Teva, Roche, Novartis, Biogen Idec, and Genzyme. She also received funds for research from the UK MS Society, National MS Society, EPSRC, Rosetree Trust; her research is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). She is an Associate Editor of <i>Neurology<\/i> for which she receives an honorarium. Dr. Carl Counsell received funding through Biogen Idec, who previously provided some funding for a departmental MS nurse. Dr. Carl Counsell has also authored a paper that was critical of the UK Risk Sharing Scheme for disease modifying therapies in MS (Sudlow, CLM, Counsell, CE. Problems with UK government\u2019s risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326:388\u2013392). The remaining authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"162"}}